Navigation Links
VLST Corporation Announces Board and Executive Management Appointments
Date:2/13/2008

- Dr. David L. Urdal, Dendreon Corporation, Joins Board of Directors, Ron

Myers Appointed Vice President Legal Affairs -

SEATTLE, Feb. 13 /PRNewswire/ -- VLST Corporation, a Seattle-based biotechnology company focused on the development of therapeutics for autoimmune and inflammatory disorders, today announced the appointments of Dr. David L. Urdal, chief scientific officer of Dendreon Corporation (Nasdaq: DNDN), to the Company's board of directors and Mr. Ron Myers, former associate general counsel, intellectual property for Corixa Corp., as vice president, legal affairs and intellectual property.

"The addition of these talented and experienced professionals to VLST's board and management comes at a time of continued advancement and growth for our Company," said Martin Simonetti, president and chief executive officer of VLST. "Both Dave and Ron will be instrumental in helping to guide our efforts as we begin advancing our novel product candidates into the clinic."

"I am pleased to be joining VLST's board and to be working again with VLST cofounder, Dr. Craig Smith. We worked together at Immunex," said Urdal. "Craig's seminal work in the discovery of Enbrel is the basis for VLST's novel drug discovery platform."

Dr. Urdal has served as Dendreon's chief scientific officer since 1995. Prior to joining Dendreon, he held various positions with Immunex Corporation, including president of Immunex Manufacturing Corporation, vice president and director of development, and head of the departments of biochemistry and membrane biochemistry. At Immunex, Dr. Urdal participated in the discovery, development and commercialization of hematopoietic growth factors, cytokines and cytokine receptors, such as GM-CSF (
'/>"/>

SOURCE VLST Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AGA Medical Corporation Receives European CE Mark Approval for the AMPLATZER(R) Duct Occluder II
2. AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
3. LifeCell Corporation Revises Full Year 2007 Preliminary Results and Schedules Fourth Quarter 2007 Financial Results Conference Call; February 27, 2008 at 10:00 a.m. Eastern
4. Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months
5. Digirad Corporation to Receive Frost & Sullivan 2007 North American Award for Product Strategy
6. Finkelstein Thompson LLP Announces Filing of Securities Fraud Class Action Against CellCyte Genetics Corporation
7. DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results
8. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
9. CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVTs Innovative Stent Coating Technology
10. DURECT Corporation Invites You to Join Its Fourth Quarter 2007 Earnings Conference Call
11. Baxa Corporation Launches New Web Site
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, has ... an emerging biomedical company acquiring, developing, manufacturing, and marketing ... Free report download: http://equitiesiq.com/reports/alliqua/ , In late ... and Board, which launched the company’s new strategy to ...
(Date:1/14/2014)... January 14, 2014 In recent years, ... and methods in product development and promotion has led ... This mistrust, fueled by concerns about the insidious impact ... reports of spectacular fines to the world’s biggest pharmas ...
(Date:1/14/2014)... Cardiff, UK (PRWEB) January 13, 2014 ... leader with more than 20 years in the industry, ... and photonics . Hainsey will serve as the society’s ... have Dr. Hainsey join SPIE as our Technology Strategist, ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 BioMedomics, Inc. ... ultra-sensitive POC diagnostic platforms and novel disease specific POC tests, ... of financing netting a total of $690,000. The investment is ... in the company. This group of private investors has significant ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2BioMedomics, Inc. Closes $690K Round of Financing 2
... naturally occurring antibodies contained in, GAMMAGARD LIQUID ... disease, CHICAGO, April 15 The University ... (NYSE: BAX ) today,announced data from a ... [Immune Globulin Intravenous (Human)] (IGIV),marketed as KIOVIG in ...
... BIRMINGHAM, Ala., and CEDARHURST, N.Y., April 15 ,BioHorizons, ... of Implant Logic Systems, Ltd. ("ILS"), first announced ... as a subsidiary of,BioHorizons. Steve Boggan, CEO of ... offering to include VIP Virtual Implant Placement,planning software ...
... PALO ALTO, Calif., April 15 CV Therapeutics,Inc. ... Capital has agreed to pay,CV Therapeutics up to ... percent of,CV Therapeutics, royalty on North American sales ... on closing,of the transaction and could receive a ...
Cached Biology Technology:Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 2Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 3Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 4Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 5BioHorizons Announces the Purchase of Implant Logic Systems 2CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection 2CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection 3
(Date:7/9/2014)... which animals can be found, concern mounts over the ... range for a host mean new territory for its ... of UC Santa Barbara scientists, including parasitologists Ryan Hechinger ... Journal of Biogeography , Hechinger, Kuris and colleagues ... Hosts may actually lose their parasites when the hosts ...
(Date:7/9/2014)... derived from the oils produced by algae may offer ... this goal, optimization of cost effective strategies for large-scale ... needed. Sapphire Energy has developed an innovative solution to ... systems, described in Industrial Biotechnology , a peer-reviewed ... is available on the Industrial Biotechnology ...
(Date:7/9/2014)... Ill. With over 100 diseases that can attack ... top of the most wanted list? University of Illinois ... that more research is needed on the fungus that ... with cool, damp growing conditions but Macrophomina phaseolina ... and dry drought conditions. , "As the climate continues ...
Breaking Biology News(10 mins):Not at home on the range 2Not at home on the range 3Not at home on the range 4Controlling contamination in open algae ponds for biofuels 2Climate change provides good growing conditions for charcoal rot in soybeans 2Climate change provides good growing conditions for charcoal rot in soybeans 3
... The University of Nottingham are to receive more than 5 ... make rural living in both the UK and India more ... opportunities for small scale energy generation through renewable sources, developing ... of mobile technologies to grow wealth in rural communities. , ...
... landscapes have undergone great change in recent decades, but species ... roe deer, Spanish ibex, red deer and wild boar. ... the effects of changes in land use on the past, ... last few decades there has been an increase in the ...
... serious gastric disorders including stomach cancer may be a step ... chemist. In the first published study of its kind, ... found a carbohydrate-based antigen caused mice to develop antibodies against ... the first jab at a sugar-based vaccine against Helicobacter ...
Cached Biology News:Nottingham researchers help bridge the urban and rural divide in the UK and India 2Nottingham researchers help bridge the urban and rural divide in the UK and India 3Nottingham researchers help bridge the urban and rural divide in the UK and India 4Changes in land use favor the expansion of wild ungulates 2
... Channel Cell Lines ,High Quality, Functionally-Validated, Ion ... well known for having a critical role ... have a key function in pain, CNS ... channels have been investigated in therapeutic areas, ...
Mouse monoclonal antibody raised against a full length recombinant SLC25A11. NCBI Entrez Gene ID = SLC25A11...
... antibody raised against a partial ... Immunogen: TOPORS (NP_005793, 98 ... recombinant protein with GST tag. ... NM_005802 ...
Mouse monoclonal antibody raised against a full length recombinant SNAPC5. NCBI Entrez Gene ID = SNAPC5...
Biology Products: